X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
1st-line treatment (2) 2
cancer (2) 2
carcinoma, non-small-cell lung - drug therapy (2) 2
carcinoma, non-small-cell lung - genetics (2) 2
carcinoma, non-small-cell lung - mortality (2) 2
care and treatment (2) 2
chemotherapy (2) 2
gefitinib (2) 2
humans (2) 2
index medicus (2) 2
lung cancer, non-small cell (2) 2
lung neoplasms - drug therapy (2) 2
lung neoplasms - genetics (2) 2
lung neoplasms - mortality (2) 2
mutation (2) 2
oncology (2) 2
receptor, epidermal growth factor - genetics (2) 2
tumors (2) 2
adenocarcinoma (1) 1
administration, intravenous (1) 1
administration, oral (1) 1
adult (1) 1
afatinib (1) 1
aged (1) 1
aged, 80 and over (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
asia (1) 1
biopsy (1) 1
cancer therapies (1) 1
carboplatin - administration & dosage (1) 1
carboplatin-paclitaxel (1) 1
carcinoma, non-small-cell lung - enzymology (1) 1
carcinoma, non-small-cell lung - pathology (1) 1
cell biology (1) 1
cell lung-cancer (1) 1
chemotherapy-naive patients (1) 1
chi-square distribution (1) 1
cisplatin - administration & dosage (1) 1
clinical trials (1) 1
datasets (1) 1
deoxycytidine - administration & dosage (1) 1
deoxycytidine - analogs & derivatives (1) 1
disease control (1) 1
disease-free survival (1) 1
dna mutational analysis (1) 1
double-blind method (1) 1
drug administration schedule (1) 1
egfr (1) 1
epidermal growth factor (1) 1
epidermal growth factor receptor (1) 1
epidermal growth factor receptors (1) 1
erlotinib (1) 1
erlotinib hydrochloride (1) 1
female (1) 1
first line (1) 1
front-line chemotherapy (1) 1
gene-mutations (1) 1
genetic aspects (1) 1
genetic predisposition to disease (1) 1
growth factors (1) 1
growth-factor-receptor (1) 1
hematology, oncology and palliative medicine (1) 1
icotinib (1) 1
kaplan-meier estimate (1) 1
kinases (1) 1
lung cancer (1) 1
lung neoplasms - enzymology (1) 1
lung neoplasms - pathology (1) 1
male (1) 1
medical colleges (1) 1
medical services (1) 1
medicine, research & experimental (1) 1
meta-analysis as topic (1) 1
middle aged (1) 1
molecular predictors (1) 1
multicenter (1) 1
mutation - genetics (1) 1
neoplasms (1) 1
non-small cell lung carcinoma (1) 1
non-small-cell lung cancer (1) 1
non‐small‐cell lung cancer (1) 1
nsclc (1) 1
open-label (1) 1
original (1) 1
original articles (1) 1
patient outcomes (1) 1
patients (1) 1
permutations (1) 1
phase-ii trial (1) 1
phase-iii trial (1) 1
phenotype (1) 1
prognosis (1) 1
progression-free survival (1) 1
proportional hazards models (1) 1
protein kinase inhibitors - administration & dosage (1) 1
protein kinase inhibitors - therapeutic use (1) 1
quinazolines - administration & dosage (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 777 - 786
Summary Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly... 
Hematology, Oncology and Palliative Medicine | PHASE-III TRIAL | CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | GEFITINIB | MULTICENTER | THERAPY | NSCLC | ONCOLOGY | ADENOCARCINOMA | OPEN-LABEL | EGFR | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Time Factors | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Administration, Intravenous | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Care and treatment | Chemotherapy | Clinical trials | Lung cancer, Non-small cell | Antineoplastic agents | Tumors | Cancer | Index Medicus
Journal Article
Journal of Cellular and Molecular Medicine, ISSN 1582-1838, 08/2014, Volume 18, Issue 8, pp. 1519 - 1539
Patients with non‐small‐cell lung cancer (NSCLC) appear to gain particular benefit from treatment with epidermal growth factor receptor (EGFR) tyrosine‐kinase... 
mutation | afatinib | epidermal growth factor receptor (EGFR) | erlotinib | non‐small‐cell lung cancer (NSCLC) | tyrosine‐kinase inhibitor | gefitinib | first line | icotinib | Tyrosine-kinase inhibitor | Icotinib | Afatinib | Erlotinib | First line | Non-small-cell lung cancer (NSCLC) | Epidermal growth factor receptor (EGFR) | Mutation | Gefitinib | GENE-MUTATIONS | MEDICINE, RESEARCH & EXPERIMENTAL | 1ST-LINE TREATMENT | GROWTH-FACTOR-RECEPTOR | PROGRESSION-FREE SURVIVAL | FRONT-LINE CHEMOTHERAPY | non-small-cell lung cancer (NSCLC) | tyrosine-kinase inhibitor | CELL BIOLOGY | CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | CHEMOTHERAPY-NAIVE PATIENTS | PHASE-II TRIAL | MOLECULAR PREDICTORS | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Meta-Analysis as Topic | Prognosis | Carcinoma, Non-Small-Cell Lung - genetics | Lung Neoplasms - mortality | Humans | Survival Rate | Mutation - genetics | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - therapeutic use | Review Literature as Topic | Carcinoma, Non-Small-Cell Lung - drug therapy | Care and treatment | Chemotherapy | Genetic aspects | Lung cancer, Non-small cell | Patient outcomes | Cancer | Epidermal growth factor | Kinases | Cancer therapies | Lung cancer | Tyrosine | Permutations | Epidermal growth factor receptors | Medical services | Non-small cell lung carcinoma | Oncology | Disease control | Patients | Datasets | Studies | Biopsy | Writing | Growth factors | Tumors | Original
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.